{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:31:57Z","timestamp":1787585517347,"version":"build-2736575974"},"reference-count":177,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Li Ka Shing Institute of Virology"},{"id":[{"id":"https:\/\/ror.org\/04xrjem68","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The ability to facilitate cellular degradation or achieve therapeutic destruction of targeted noxious DNA is recognized as a major goal for the treatment of various viral infections. In the case of chronic hepatitis B, targeted DNA degradation of the episomal viral genome found in the nucleus of infected hepatocytes is key to achieving a true cure. However, mechanisms of targeted DNA degradation without excessive broadscale cytotoxicity are still under investigation by researchers. This review summarizes several current systems known to have the ability to target nuclear-localized DNA, including endogenous methods of DNA degradation that may be harnessed therapeutically and exogenous methods such as CRISPR or other xenobiotics, with a focus on their potential application in hepatitis B treatment.<\/jats:p>","DOI":"10.3390\/v18090929","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:49:34Z","timestamp":1787582974000},"page":"929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting cccDNA for Degradation: Endogenous- and Exogenous-Based Methods of Nuclear-Localized DNA Destruction in the Context of Chronic Hepatitis B Infection"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3591-1317","authenticated-orcid":false,"given":"Cassie","family":"Thompson","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-4940","authenticated-orcid":false,"given":"Vanessa","family":"Meier-Stephenson","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada"},{"name":"Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada"},{"name":"Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","unstructured":"(2026, July 17). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Chan","year":"2014","journal-title":"Lancet"},{"key":"ref_4","unstructured":"(2026, July 17). Immunization Coverage. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Boonstra, A., and Sari, G. (2025). HBV cccDNA: The Molecular Reservoir of Hepatitis B Persistence and Challenges to Achieve Viral Eradication. Biomolecules, 15.","DOI":"10.3390\/biom15010062"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Moreno, A., and Ploss, A. (2024). Mechanisms of Hepatitis B Virus cccDNA and Minichromosome Formation and HBV Gene Transcription. Viruses, 16.","DOI":"10.3390\/v16040609"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","article-title":"Hepatitis B virus cccDNA is formed through distinct repair processes of each strand","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF01703079","article-title":"Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell","volume":"8","author":"Bock","year":"1994","journal-title":"Virus Genes"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Allweiss, L., and Dandri, M. (2017). The Role of cccDNA in HBV Maintenance. Viruses, 9.","DOI":"10.3390\/v9060156"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.livres.2025.09.002","article-title":"Hepatitis B virus integration and hepatocarcinogenesis","volume":"9","author":"Ma","year":"2025","journal-title":"Liver Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tu, T., Budzinska, M.A., Shackel, N.A., and Urban, S. (2017). HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses, 9.","DOI":"10.3390\/v9040075"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1073\/pnas.0403925101","article-title":"Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration","volume":"101","author":"Bill","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/jgh.14075","article-title":"Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy","volume":"33","author":"Hu","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pollicino, T., and Caminiti, G. (2021). HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 13.","DOI":"10.3390\/v13030368"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, D., Hamadalnil, Y., and Tu, T. (2024). Hepatitis B Viral Protein HBx: Roles in Viral Replication and Hepatocarcinogenesis. Viruses, 16.","DOI":"10.3390\/v16091361"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Clinical Practice Guidelines Committee Chair, Osiowy, C., Panel Members, Alvarez, F., Coffin, C.S., Cooper, C.L., Fung, S.K., Ko, H.H., Poulin, S., and van Gennip, J. (2025). The management of chronic hepatitis B: 2025 Guidelines update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. Can. Liver J., 8, 368\u2013401.","DOI":"10.3138\/canlivj-2025-0012-e"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101360","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: Replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr. Opin. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12985-024-02512-w","article-title":"Efficacy of short-term Peg-IFN \u03b1-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: A retrospective cohort study","volume":"21","author":"Li","year":"2024","journal-title":"Virol. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/apt.17670","article-title":"Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy","volume":"58","author":"Gao","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","article-title":"Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection","volume":"394","author":"Hou","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103400","DOI":"10.1016\/j.eclinm.2025.103400","article-title":"Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: A randomized, double-blind, placebo-controlled, multicenter phase II study","volume":"87","author":"Wang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106446","DOI":"10.1016\/j.jinf.2025.106446","article-title":"Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trial","volume":"90","author":"Zhang","year":"2025","journal-title":"J. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.cdd.4401161","article-title":"Degradation of chromosomal DNA during apoptosis","volume":"10","author":"Nagata","year":"2003","journal-title":"Cell Death Differ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/bi001041a","article-title":"Characterization of Human DNase I Family Endonucleases and Activation of DNase \u03b3 during Apoptosis","volume":"40","author":"Shiokawa","year":"2001","journal-title":"Biochemistry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/34214","article-title":"Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis","volume":"391","author":"Sakahira","year":"1998","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ceb.2009.08.008","article-title":"Cellular and nuclear degradation during apoptosis","volume":"21","author":"He","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1073\/pnas.0913089107","article-title":"Caspase 3\/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks","volume":"107","author":"Larsen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1021\/acs.jmedchem.8b01668","article-title":"Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives","volume":"62","author":"Cong","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1502390112","article-title":"Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1073\/pnas.1502400112","article-title":"Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41419-021-03924-0","article-title":"Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models","volume":"12","author":"Clark","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/v4112945","article-title":"Modulation of Apoptotic Signaling by the Hepatitis B Virus X Protein","volume":"4","author":"Rawat","year":"2012","journal-title":"Viruses"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2022.02.016","article-title":"Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection","volume":"77","author":"Montanari","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS\u2013cGAMP\u2013STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2013.06.007","article-title":"Catastrophic Nuclear Envelope Collapse in Cancer Cell Micronuclei","volume":"154","author":"Hatch","year":"2013","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.molcel.2020.12.037","article-title":"ER-directed TREX1 limits cGAS activation at micronuclei","volume":"81","author":"Mohr","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100514","DOI":"10.1016\/j.jhepr.2022.100514","article-title":"Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells","volume":"4","author":"Tu","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e01295-25","DOI":"10.1128\/jvi.01295-25","article-title":"Replication-driven HBV cccDNA loss in chimeric mice with humanized livers","volume":"99","author":"Zhang","year":"2025","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41418-018-0266-5","article-title":"Nucleophagy: From homeostasis to disease","volume":"26","author":"Papandreou","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.tcb.2021.12.008","article-title":"Degradation of nuclear components via different autophagy pathways","volume":"32","author":"Li","year":"2022","journal-title":"Trends Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature15548","article-title":"Autophagy mediates degradation of nuclear lamina","volume":"527","author":"Dou","year":"2015","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41556-020-00579-5","article-title":"SIRT1 is downregulated by autophagy in senescence and ageing","volume":"22","author":"Xu","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.7150\/ijms.43491","article-title":"HBx mediated Increase of SIRT1 Contributes to HBV-related Hepatocellular Carcinoma Tumorigenesis","volume":"17","author":"Wang","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.celrep.2014.08.074","article-title":"Dnase2a Deficiency Uncovers Lysosomal Clearance of Damaged Nuclear DNA via Autophagy","volume":"9","author":"Lan","year":"2014","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1083\/jcb.201212110","article-title":"Lysosome-mediated processing of chromatin in senescence","volume":"202","author":"Ivanov","year":"2013","journal-title":"J. Cell Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.chom.2010.01.007","article-title":"Autophagy Protects against Sindbis Virus Infection of the Central Nervous System","volume":"7","author":"Orvedahl","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41420-024-02122-z","article-title":"Colchicine-mediated selective autophagic degradation of HBV core proteins inhibits HBV replication and HBV-related hepatocellular carcinoma progression","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e00014-24","DOI":"10.1128\/mmbr.00014-24","article-title":"Hepatitis B virus entry, assembly, and egress","volume":"88","author":"Chuang","year":"2024","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1073\/pnas.0911373107","article-title":"The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication","volume":"107","author":"Sir","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1128\/JVI.02627-10","article-title":"Subversion of Cellular Autophagy Machinery by Hepatitis B Virus for Viral Envelopment","volume":"85","author":"Li","year":"2011","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.tibs.2025.02.006","article-title":"AID\/APOBEC: An expanding repertoire of targets and functions","volume":"50","author":"Budzko","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.tig.2021.07.003","article-title":"APOBECs orchestrate genomic and epigenomic editing across health and disease","volume":"37","author":"Weischedel","year":"2021","journal-title":"Trends Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20709","DOI":"10.1016\/S0021-9258(19)36836-X","article-title":"The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase","volume":"268","author":"Navaratnam","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.virol.2015.03.012","article-title":"APOBECs and virus restriction","volume":"479\u2013480","author":"Harris","year":"2015","journal-title":"Virology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nsmb.1744","article-title":"APOBEC3 proteins mediate the clearance of foreign DNA from human cells","volume":"17","author":"Stenglein","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature00939","article-title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein","volume":"418","author":"Sheehy","year":"2002","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.chembiol.2017.10.007","article-title":"APOBEC Enzymes as Targets for Virus and Cancer Therapy","volume":"25","author":"Olson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nsmb.3344","article-title":"Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B","volume":"24","author":"Shi","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1093\/nar\/gkt246","article-title":"APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure","volume":"41","author":"Holtz","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e01879-24","DOI":"10.1128\/jvi.01879-24","article-title":"APOBEC-1 cofactors regulate APOBEC3-induced mutations in hepatitis B virus","volume":"99","author":"Chen","year":"2025","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41418-024-01412-4","article-title":"hnRNPA2B1 deacetylation by SIRT6 restrains local transcription and safeguards genome stability","volume":"32","author":"Chen","year":"2025","journal-title":"Cell Death Differ."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eaav0758","DOI":"10.1126\/science.aav0758","article-title":"Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses","volume":"365","author":"Wang","year":"2019","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"gkag149","DOI":"10.1093\/nar\/gkag149","article-title":"hnRNPA2B1 induces HBV cccDNA degradation by recruiting APOBEC3B","volume":"54","author":"Fu","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"ref_69","first-page":"37","article-title":"A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo","volume":"14","author":"Zuo","year":"2023","journal-title":"Protein Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.21187","article-title":"Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication","volume":"43","author":"Bonvin","year":"2006","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Vartanian, J.-P., Henry, M., Marchio, A., Susp\u00e8ne, R., Aynaud, M.-M., Gu\u00e9tard, D., Cervantes-Gonzalez, M., Battiston, C., Mazzaferro, V., and Pineau, P. (2010). Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000928"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.jhepr.2021.100354","article-title":"Control of APOBEC3B induction and cccDNA decay by NF-\u03baB and miR-138-5p","volume":"3","author":"Riedl","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hep.20801","article-title":"APOBEC-mediated interference with hepadnavirus production","volume":"42","author":"Kann","year":"2005","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and Tumor Necrosis Factor-\u03b1 Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1134\/S0006297925603326","article-title":"Antiviral and Mutagenic Effects of APOBEC Deaminases A3C, A3D, and A3H in a Hepatitis B Virus Model","volume":"91","author":"Karandashov","year":"2026","journal-title":"Biochem. Mosc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.antiviral.2017.11.006","article-title":"APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription","volume":"149","author":"Chen","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1126\/science.1092066","article-title":"Inhibition of Hepatitis B Virus Replication by APOBEC3G","volume":"303","author":"Turelli","year":"2004","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.2147\/IDR.S484265","article-title":"The Mechanism of APOBEC3B in Hepatitis B Virus Infection and HBV Related Hepatocellular Carcinoma Progression, Therapeutic and Prognostic Potential","volume":"17","author":"Yang","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e49568","DOI":"10.15252\/embr.201949568","article-title":"Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20","volume":"22","author":"Stadler","year":"2021","journal-title":"EMBO Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/srep00806","article-title":"APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells","volume":"2","author":"Shinohara","year":"2012","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/embor.2011.46","article-title":"APOBEC3A can activate the DNA damage response and cause cell-cycle arrest","volume":"12","author":"Landry","year":"2011","journal-title":"EMBO Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature11881","article-title":"APOBEC3B is an enzymatic source of mutation in breast cancer","volume":"494","author":"Burns","year":"2013","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13059-023-03115-4","article-title":"Acute expression of human APOBEC3B in mice results in RNA editing and lethality","volume":"24","author":"Temiz","year":"2023","journal-title":"Genome Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/jvh.12110","article-title":"Full genome ultra-deep pyrosequencing associates G-to-A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B","volume":"20","author":"Beggel","year":"2013","journal-title":"J. Viral Hepat."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/jhep.2001.28459","article-title":"Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?","volume":"34","author":"Nair","year":"2001","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1073\/pnas.91.9.3764","article-title":"Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice","volume":"91","author":"Guidotti","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4049\/jimmunol.0902761","article-title":"CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions","volume":"184","author":"Phillips","year":"2010","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"106424","DOI":"10.1016\/j.antiviral.2026.106424","article-title":"Understanding HBV immunopathogenesis to inform future immune-based therapies","volume":"251","author":"Bossis","year":"2026","journal-title":"Antivir. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus\u2013specific B cells in chronic hepatitis B infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection","volume":"81","author":"Boni","year":"2007","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"112238","DOI":"10.1016\/j.ejmech.2020.112238","article-title":"Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes","volume":"193","author":"Patinote","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000534535","article-title":"Possibility of PD-1\/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection","volume":"42","author":"Su","year":"2023","journal-title":"Dig. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/HEP.0000000000001006","article-title":"A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative","volume":"81","author":"Qian","year":"2025","journal-title":"Hepatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: A phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11427-022-2230-4","article-title":"Current progress in the development of prophylactic and therapeutic vaccines","volume":"66","author":"Li","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.jhepr.2021.100361","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"105338","DOI":"10.1016\/j.jddst.2024.105338","article-title":"Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery","volume":"92","author":"Aljabali","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrg2749","article-title":"CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea","volume":"11","author":"Marraffini","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-022-00636-2","article-title":"Advances in CRISPR therapeutics","volume":"19","author":"Chavez","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_107","first-page":"3797214","article-title":"CRISPR\/Cas9 System: A Bacterial Tailor for Genomic Engineering","volume":"2018","author":"Lone","year":"2018","journal-title":"Genet. Res. Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA\u2013Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102138","DOI":"10.1016\/j.omtn.2024.102138","article-title":"Recent advances in CRISPR-Cas9-based genome insertion technologies","volume":"35","author":"Chen","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-139575","article-title":"Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent \u03b2-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells","volume":"136","author":"Frangoul","year":"2020","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.tim.2017.04.005","article-title":"Antiviral Goes Viral: Harnessing CRISPR\/Cas9 to Combat Viruses in Humans","volume":"25","author":"Soppe","year":"2017","journal-title":"Trends Microbiol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Karpov, D.S., Demidova, N.A., Kulagin, K.A., Shuvalova, A.I., Kovalev, M.A., Simonov, R.A., Karpov, V.L., Snezhkina, A.V., Kudryavtseva, A.V., and Klimova, R.R. (2022). Complete and Prolonged Inhibition of Herpes Simplex Virus Type 1 Infection In Vitro by CRISPR\/Cas9 and CRISPR\/CasX Systems. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314847"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"106326","DOI":"10.1016\/j.antiviral.2025.106326","article-title":"Suppression of HBV replication and expression by CRISPR\/Cas9 ribonucleoproteins","volume":"245","author":"Hill","year":"2026","journal-title":"Antivir. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/gt.2015.2","article-title":"Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)\/CRISPR-associated Cas9 system to disrupt the hepatitis B virus","volume":"22","author":"Zhen","year":"2015","journal-title":"Gene Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting Hepatitis B Virus with CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2556728","DOI":"10.1080\/22221751.2025.2556728","article-title":"Highly stable Cas9 promotes HBV genome destruction by antagonizing HSC70-mediated degradation","volume":"14","author":"Li","year":"2025","journal-title":"Emerg. Microbes Infect."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.omtn.2023.02.001","article-title":"Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9","volume":"31","author":"Kostyushev","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/boc.202200060","article-title":"Hepatitis B virus movement through the hepatocyte: An update","volume":"114","author":"Prange","year":"2022","journal-title":"Biol. Cell"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Martinez, M.G., Smekalova, E., Combe, E., Gregoire, F., Zoulim, F., and Testoni, B. (2022). Gene Editing Technologies to Target HBV cccDNA. Viruses, 14.","DOI":"10.3390\/v14122654"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e02888-21","DOI":"10.1128\/mbio.02888-21","article-title":"CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants","volume":"13","author":"Martinez","year":"2022","journal-title":"mBio"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/s41598-019-38526-6","article-title":"Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR\/Cas9","volume":"9","author":"Kostyushev","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/hep4.2014","article-title":"Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy","volume":"6","author":"Murai","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"102634","DOI":"10.1016\/j.omtn.2025.102634","article-title":"Recent applications, future perspectives, and limitations of the CRISPR-Cas system","volume":"36","author":"Park","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Seijas, A., Cora, D., Novo, M., Al-Soufi, W., S\u00e1nchez, L., and Arana, \u00c1.J. (2025). CRISPR\/Cas9 Delivery Systems to Enhance Gene Editing Efficiency. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202503.2038.v1"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Duan, L., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., and Liang, Y. (2021). Nanoparticle Delivery of CRISPR\/Cas9 for Genome Editing. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.673286"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"152466","DOI":"10.1016\/j.ijbiomac.2026.152466","article-title":"Critical role of Cas9 aggregation on in vitro DNA cleavage","volume":"366","author":"Cora","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Ewaisha, R., and Anderson, K.S. (2023). Immunogenicity of CRISPR therapeutics\u2014Critical considerations for clinical translation. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1138596"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"105834","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: Current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Kaupbayeva, B., Tsoy, A., Safarova (Yantsen), Y., Nurmagambetova, A., Murata, H., Matyjaszewski, K., and Askarova, S. (2024). Unlocking Genome Editing: Advances and Obstacles in CRISPR\/Cas Delivery Technologies. J. Funct. Biomater., 15.","DOI":"10.3390\/jfb15110324"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wang, Y., and Shao, W. (2023). Innate Immune Response to Viral Vectors in Gene Therapy. Viruses, 15.","DOI":"10.3390\/v15091801"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Garrigue","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/mt.2011.289","article-title":"Retroviral Integrations in Gene Therapy Trials","volume":"20","author":"Biasco","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics with Endogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"114990","DOI":"10.1016\/j.addr.2023.114990","article-title":"Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications","volume":"200","author":"Jeong","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymthe.2024.10.003","article-title":"Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"100627","DOI":"10.1016\/j.jve.2026.100627","article-title":"Antiviral efficacy of LNP-delivered IFN-\u03b114-ApoAI mRNA for chronic hepatitis B","volume":"12","author":"Yang","year":"2026","journal-title":"J. Virus Erad."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00253-024-13056-y","article-title":"Engineering Cas9: Next generation of genomic editors","volume":"108","author":"Kovalev","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Kumar, A., Combe, E., Mougen\u00e9, L., Zoulim, F., and Testoni, B. (2024). Applications of CRISPR\/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics. Viruses, 16.","DOI":"10.3390\/v16101565"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/crispr.2024.0038","article-title":"Establishment of a Cleavage-Based Single-Plasmid Dual-Luciferase Surrogate Reporter for the Cleavage Efficiency Evaluation of CRISPR-Cas12a Systems and Its Primary Application","volume":"7","author":"Shi","year":"2024","journal-title":"CRISPR J."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Kasianchuk, N., Dobrowolska, K., Harkava, S., Bretcan, A., Zar\u0119bska-Michaluk, D., Jaroszewicz, J., Flisiak, R., and Rzymski, P. (2023). Gene-Editing and RNA Interference in Treating Hepatitis B: A Review. Viruses, 15.","DOI":"10.3390\/v15122395"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","article-title":"Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo","volume":"30","author":"Gorsuch","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_147","unstructured":"Yuen, M.-F., Jucov, A., Gane, E., Harrison, E.B., Cott, A.V., Chandiramani, A., Leatherbury, N., Fry, J., Smith, J., and Gorsuch, C.L. (2025, January 7\u201311). PBGENE-HBV, a First-in-class Gene Editing Therapy for Chronic Hepatitis B, Demonstrates Safety and Antiviral Activity in Early Cohorts. Proceedings of the Liver Meeting\u00ae 2025, Washington, DC, USA."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen Mustard Therapy; Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin\u2019s Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"J. Am. Med. Assoc."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2013.07.006","article-title":"From old alkylating agents to new minor groove binders","volume":"89","author":"Puyo","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Weber, G.F. (2014). DNA Damaging Drugs. Molecular Therapies of Cancer, Springer International Publishing.","DOI":"10.1007\/978-3-319-13278-5_2"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s40495-022-00289-6","article-title":"The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment","volume":"8","author":"Lavanya","year":"2022","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e02230-18","DOI":"10.1128\/JVI.02230-18","article-title":"Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA","volume":"93","author":"Sheraz","year":"2019","journal-title":"J. Virol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbrc.2018.08.195","article-title":"Daunorubicin, a topoisomerase II poison, suppresses viral production of hepatitis B virus by inducing cGAS-dependent innate immune response","volume":"504","author":"Imai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA","volume":"339","author":"Wu","year":"2013","journal-title":"Science"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"110639","DOI":"10.1016\/j.virol.2025.110639","article-title":"Novel insights into the role of cGAS-STING signaling in HBV infection","volume":"611","author":"Zhu","year":"2025","journal-title":"Virology"},{"key":"ref_156","first-page":"189024","article-title":"Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?","volume":"1878","author":"Kciuk","year":"2023","journal-title":"Biochim. Biophys. Acta BBA\u2014Rev. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1747-1028-8-8","article-title":"To divide or not to divide: Revisiting liver regeneration","volume":"8","author":"Miyaoka","year":"2013","journal-title":"Cell Div."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"van den Boogaard, W.M.C., Komninos, D.S.J., and Vermeij, W.P. (2022). Chemotherapy Side-Effects: Not All DNA Damage Is Equal. Cancers, 14.","DOI":"10.3390\/cancers14030627"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.cmi.2022.02.042","article-title":"Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies","volume":"28","author":"Mustafayev","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.3748\/wjg.v20.i24.7675","article-title":"Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy","volume":"20","author":"Jang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1440-1746.2012.07280.x","article-title":"Hepatitis B virus reactivation associated with anti-neoplastic therapy","volume":"28","author":"Yeo","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1385\/MO:21:1:67","article-title":"Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin\u2019s lymphoma","volume":"21","author":"Ozguroglu","year":"2004","journal-title":"Med. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/SLA.0b013e318262b218","article-title":"Posthepatectomy HBV Reactivation in Hepatitis B\u2013Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients with Preoperative Low HBV-DNA Levels","volume":"257","author":"Huang","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12967-025-07640-7","article-title":"IAPs in cancers: Molecular mechanisms, clinical prognostic value, and translational therapeutic potential","volume":"24","author":"Teng","year":"2026","journal-title":"J. Transl. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","article-title":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","volume":"78","author":"Gane","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"102036","DOI":"10.1016\/j.toxrep.2025.102036","article-title":"Immune-related adverse events in immunotherapy: Challenges in diagnosis, monitoring, and management","volume":"14","author":"Siddiqui","year":"2025","journal-title":"Toxicol. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"102636","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"198191","DOI":"10.1016\/j.virusres.2020.198191","article-title":"Development of an in vivo delivery system for CRISPR\/Cas9-mediated targeting of hepatitis B virus cccDNA","volume":"290","author":"Kayesh","year":"2020","journal-title":"Virus Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"102112","DOI":"10.1016\/j.omtn.2023.102112","article-title":"Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo","volume":"35","author":"Smekalova","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"He, W., Zheng, Z., Zhao, Q., Zhang, R., and Zheng, H. (2024). Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B. Pathogens, 13.","DOI":"10.3390\/pathogens13121100"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete Spectrum of CRISPR\/Cas9-induced Mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Shechter, O., Sausen, D.G., Dahari, H., Vaillant, A., Cotler, S.J., and Borenstein, R. (2025). Functional Cure for Hepatitis B Virus: Challenges and Achievements. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083633"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"106355","DOI":"10.1016\/j.antiviral.2026.106355","article-title":"Overview of gene editing strategies against HBV","volume":"247","author":"Janetzki","year":"2026","journal-title":"Antivir. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"106321","DOI":"10.1016\/j.antiviral.2025.106321","article-title":"Update on combination therapies against HBV in clinical investigations","volume":"245","author":"Mak","year":"2026","journal-title":"Antivir. Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:55:36Z","timestamp":1787583336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":177,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["v18090929"],"URL":"https:\/\/doi.org\/10.3390\/v18090929","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}